


SYNTHESIS OF 14-PHENYLPROSTAGLANDINS E<sub>1</sub>, A<sub>1</sub> AND F<sub>2α</sub>

Robert T. Buckler\* and David L. Garling  
 Chemistry Department, Miles Laboratories, Inc.  
 Elkhart, Indiana 46514

(Received in USA 27 January 1978; received in UK for publication 2 May 1978)


In searching for prostaglandins of more specific biological activities, we chose to make analogs having a 14-phenyl substituent. An examination of space-filling molecular models suggested that such a structural transformation might constrain the lower arm of the PG skeleton in a conformation favoring increased interaction between the two arms. Such interaction would reduce the number of possible conformations and perhaps lead to a sharper profile of pharmacological activities.

The synthetic route chosen for the E-type prostaglandins I was based on the conjugate addition of the organo cuprate III to the known cyclopentenones II. This reaction is known to produce E-type prostaglandins possessing the all-*trans* stereochemistry at the ring atoms.<sup>1</sup>



The precursor of cuprate III, the E-iodovinyl alcohol 5, was prepared from 1-phenyl-2-heptanone 1<sup>2</sup> as shown in Scheme I. Condensation of 1 with ethyl formate produced 1-formyl-1-phenyl-2-heptanone, isolated and characterized as the copper-chelated Z-isomer 2 (recry from hexane, mp 85-88°C, 50%).<sup>3</sup> The free enol of 2 was liberated with HCl-CH<sub>2</sub>Cl<sub>2</sub> and treated with *p*-toluene-sul-

fonyl chloride-pyridine. This produced the enol tosylate 3 (mp 90-92°C, recryst from hexane), assigned the *Z* configuration on the basis of the shift of the vinyl proton in its  $^1\text{H}$  NMR spectrum



(7.4  $\delta$ ,  $\text{CDCl}_3$ ). Vinyl protons  $\beta$ -*trans* to carbonyl functions exhibit chemical shifts in the range 7.2  $\delta$  to 7.4  $\delta$ . Protons  $\beta$ -*cis* to carbonyl groups are deshielded and shifted downfield to about 8.1  $\delta$ <sup>4</sup>.

The acid-catalyzed reaction of 3 with 2 equivalents of NaI in acetone gave the *E*-iodo-vinyl ketone 4 (vinyl H at 8.0  $\delta$ ,  $\text{CDCl}_3$ ), which was not characterized but reduced directly ( $\text{NaBH}_4$ -ethanol) to give *dl-E*-3-hydroxy-1-iodo-1-octene 5, isolated as a pale golden oil (vinyl H at 7.2  $\delta$ ,  $\text{CDCl}_3$ , 22% yield overall). Alcohol 5 was protected as the ethyl vinyl ether adduct, lithiated (*t*-BuLi, -70°C, ether), and combined with the hexamethyl phosphorous triamide complex of copper *n*-propyl acetylide to generate the cuprate cluster III<sup>1</sup>. This reactant transferred the vinyl species (-40°C, 2 hrs, ether) to the protected 4-hydroxycyclopentenones II to produce, after deblocking, the PGE esters Ia and Ib.

It was not possible to resolve alcohol 5. However, we were able to obtain the 4-hydroxycyclopentenones as the optically active *R*-enantiomers IIa and IIb by the published procedures<sup>5</sup>. Thus the 14-phenyl PGEs Ia and Ib were obtained as a mixture of two isomers, epimeric at C-15. These were separated by column chromatography on silica gel, eluting with benzene-ethyl acetate. The first-eluted isomer in each case was assigned the structure of the 15-*epi* isomer (15 *R*) and the second-eluted one as the *natural* (15 *S*) isomer on the basis of the known chro-


matographic behavior of the natural PGs.<sup>6</sup> In this way we made 180 mg (12% yield) of 14-phenyl PGE<sub>1</sub> methyl ester Ia (oil  $\alpha_D = -34.9^\circ$ , rf = 0.60, m/e 444 [M+], 426 [M+ -H<sub>2</sub>O]) and 115 mg (10% yield) of the ethyl ester of 14-phenyl PGE<sub>2</sub>Ib (oil,  $\alpha_D = -17.5^\circ$ , rf = 0.62, m/e 465 [M+], 438 [M+ -H<sub>2</sub>O]).

The ester Ia, 200 mg was hydrolyzed to its corresponding free acid using the enzyme *hog liver carboxylic ester hydrolase* (EC 3.1.1.1) in 0.1 M phosphate buffer (pH 7.4, 37°C). By this we obtained 75 mg of 14-phenyl PGE<sub>1</sub> IV [oil,  $\alpha_D = -29.0^\circ$ , rf = 0.51, m/e 412 (M+ -H<sub>2</sub>O)].

50 Mg of the acid IV was dehydrated in aqueous acetic acid (50°C, 2 hrs) to give 10 mg of 14-phenyl PGA<sub>1</sub> V [oil,  $\alpha_D = 85.4^\circ$ , rf = 0.65, m/e 412 (M+)].

900 Mg of ester Ib was stereoselectively reduced using lithium perhydro-9b-borophenylhydride (PBPH)<sup>7</sup> to give 278 mg of the ethyl ester of 14-phenyl PGF<sub>2 $\alpha$</sub>  VIa [oil,  $\alpha_D = -19.2^\circ$ , rf = 0.57, m/e 458 [M+], 440 (M+ -H<sub>2</sub>O)]. A 200 mg portion of this was saponified (KOH-MeOH) to give 131 mg of the free acid, 14-phenyl PGF<sub>2 $\alpha$</sub>  VIb [oil,  $\alpha_D = -23.1^\circ$ , rf = 0.48, m/e 430 (M+), 412 (M+ -H<sub>2</sub>O)].

These PG analogs were examined in a number of pharmacological screens. Although they display some antagonism to natural PGs, their own prostaglandin-like activities are some thousand-fold less than the natural substances.



**Acknowledgement:** The authors express their gratitude to Horacio Vidrio and Carl Myers for the pharmacological screening of these compounds.

## REFERENCES

1. E. J. Corey and D. J. Beames, *J. Amer. Chem. Soc.*, 94, 7210 (1972).
2. E. H. Sund and H. R. Henze, *J. Chem. Eng. Data*, 15, 200 (1970).
3. Satisfactory elemental analysis were obtained for all intermediates. Mass Spectra were determined at 70 e.v. TLC rf values were determined on Merck silica gel 60 plates eluting with the solvent system described by M. Bygdeman, M. K. Svanborg and B. Samuelsson, *Clin. Chim. Acta*, 26 373 (1969).
- 4a. B. D. Tilak, R. B. Mitra and Z. Muljiani, *Tetrahedron*, 25, 1939 (1969).
- 4b. L. Bardon, J. Elguero, R. Jacquier, *Bull. Soc. Chim. Fr.*, 297 (1967).
- 5a. C. J. Sih, J. B. Heather, G. P. Peruzzotti, P. Price, R. Sood, and L-F. H. Lee, *J. Amer. Chem. Soc.*, 95 1676 (1973).
- 5b. J. B. Heather, R. Sood, P. Price, G. P. Peruzzotti, S. S. Lee, L-F. H. Lee, and C. J. Sih, *Tet. Lett.* (25), 2313 (1973).
6. N. H. Andersen, *J. Lipid Res.* 40, 316 (1969).
7. E. J. Corey and R. K. Varma, *J. Amer. Chem. Soc.*, 93, 7319 (1971).